341.62 USD
+0.51 (+0.15%)
Taking everything into account, AMGN scores 5 out of 10 in our fundamental rating. AMGN was compared to 533 industry peers in the Biotechnology industry. AMGN scores excellent on profitability, but there are concerns on its financial health. AMGN has a correct valuation and a medium growth rate. AMGN also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year AMGN was profitable.
AMGN had a positive operating cash flow in the past year.
Each year in the past 5 years AMGN has been profitable.
AMGN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
AMGN has a better Return On Assets (7.77%) than 93.06% of its industry peers.
AMGN's Return On Equity of 72.82% is amongst the best of the industry. AMGN outperforms 99.06% of its industry peers.
AMGN has a Return On Invested Capital of 15.39%. This is amongst the best in the industry. AMGN outperforms 95.87% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AMGN is significantly below the industry average of 18.83%.
The last Return On Invested Capital (15.39%) for AMGN is above the 3 year average (13.04%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| ROIC | 15.39% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
1.3 Margins
The Profit Margin of AMGN (19.47%) is better than 94.00% of its industry peers.
In the last couple of years the Profit Margin of AMGN has declined.
AMGN has a better Operating Margin (33.57%) than 97.19% of its industry peers.
AMGN's Operating Margin has declined in the last couple of years.
AMGN has a better Gross Margin (72.06%) than 82.18% of its industry peers.
AMGN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.57% | ||
| PM (TTM) | 19.47% | ||
| GM | 72.06% |
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
2. Health
2.1 Basic Checks
AMGN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, AMGN has more shares outstanding
The number of shares outstanding for AMGN has been reduced compared to 5 years ago.
Compared to 1 year ago, AMGN has an improved debt to assets ratio.
2.2 Solvency
The Debt to FCF ratio of AMGN is 4.28, which is a neutral value as it means it would take AMGN, 4.28 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.28, AMGN belongs to the top of the industry, outperforming 91.93% of the companies in the same industry.
A Debt/Equity ratio of 5.45 is on the high side and indicates that AMGN has dependencies on debt financing.
AMGN's Debt to Equity ratio of 5.45 is on the low side compared to the rest of the industry. AMGN is outperformed by 82.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.45 | ||
| Debt/FCF | 4.28 | ||
| Altman-Z | N/A |
ROIC/WACC1.81
WACC8.51%
2.3 Liquidity
AMGN has a Current Ratio of 1.28. This is a normal value and indicates that AMGN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of AMGN (1.28) is worse than 84.05% of its industry peers.
AMGN has a Quick Ratio of 1.28. This is a bad value and indicates that AMGN is not financially healthy enough and could expect problems in meeting its short term obligations.
AMGN has a Quick ratio of 0.99. This is amonst the worse of the industry: AMGN underperforms 86.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
AMGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.79%, which is quite good.
The Earnings Per Share has been growing slightly by 5.97% on average over the past years.
Looking at the last year, AMGN shows a quite strong growth in Revenue. The Revenue has grown by 10.56% in the last year.
AMGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.43% yearly.
EPS 1Y (TTM)13.79%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%1.08%
Revenue 1Y (TTM)10.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%12.4%
3.2 Future
Based on estimates for the next years, AMGN will show a small growth in Earnings Per Share. The EPS will grow by 4.18% on average per year.
Based on estimates for the next years, AMGN will show a small growth in Revenue. The Revenue will grow by 3.22% on average per year.
EPS Next Y8.22%
EPS Next 2Y5.36%
EPS Next 3Y4.87%
EPS Next 5Y4.18%
Revenue Next Year7.43%
Revenue Next 2Y4.6%
Revenue Next 3Y3.97%
Revenue Next 5Y3.22%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
AMGN is valuated correctly with a Price/Earnings ratio of 15.62.
95.31% of the companies in the same industry are more expensive than AMGN, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.98, AMGN is valued a bit cheaper.
The Price/Forward Earnings ratio is 15.53, which indicates a correct valuation of AMGN.
Based on the Price/Forward Earnings ratio, AMGN is valued cheaply inside the industry as 95.87% of the companies are valued more expensively.
AMGN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.79.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.62 | ||
| Fwd PE | 15.53 |
4.2 Price Multiples
AMGN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMGN is cheaper than 95.68% of the companies in the same industry.
96.44% of the companies in the same industry are more expensive than AMGN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.42 | ||
| EV/EBITDA | 12.95 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AMGN does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of AMGN may justify a higher PE ratio.
PEG (NY)1.9
PEG (5Y)2.62
EPS Next 2Y5.36%
EPS Next 3Y4.87%
5. Dividend
5.1 Amount
AMGN has a Yearly Dividend Yield of 2.83%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 74.20, AMGN pays a better dividend. On top of this AMGN pays more dividend than 98.69% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.41, AMGN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.83% |
5.2 History
The dividend of AMGN is nicely growing with an annual growth rate of 9.41%!
AMGN has paid a dividend for at least 10 years, which is a reliable track record.
AMGN has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)9.41%
Div Incr Years13
Div Non Decr Years13
5.3 Sustainability
17.20% of the earnings are spent on dividend by AMGN. This is a low number and sustainable payout ratio.
The dividend of AMGN is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP17.2%
EPS Next 2Y5.36%
EPS Next 3Y4.87%
NASDAQ:AMGN (11/26/2025, 9:58:09 AM)
341.62
+0.51 (+0.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners84.15%
Inst Owner Change-3.55%
Ins Owners0.06%
Ins Owner Change-0.85%
Market Cap183.91B
Revenue(TTM)35.97B
Net Income(TTM)7.00B
Analysts72
Price Target327.38 (-4.17%)
Short Float %2.5%
Short Ratio5.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.83% |
Yearly Dividend9.01
Dividend Growth(5Y)9.41%
DP17.2%
Div Incr Years13
Div Non Decr Years13
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.96%
Min EPS beat(2)10.28%
Max EPS beat(2)11.64%
EPS beat(4)4
Avg EPS beat(4)9.04%
Min EPS beat(4)2.49%
Max EPS beat(4)11.73%
EPS beat(8)7
Avg EPS beat(8)5.13%
EPS beat(12)10
Avg EPS beat(12)4.44%
EPS beat(16)14
Avg EPS beat(16)4.21%
Revenue beat(2)2
Avg Revenue beat(2)2.59%
Min Revenue beat(2)0.68%
Max Revenue beat(2)4.49%
Revenue beat(4)3
Avg Revenue beat(4)1.17%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)4.49%
Revenue beat(8)3
Avg Revenue beat(8)-0.21%
Revenue beat(12)4
Avg Revenue beat(12)-0.48%
Revenue beat(16)5
Avg Revenue beat(16)-0.54%
PT rev (1m)2.32%
PT rev (3m)2.42%
EPS NQ rev (1m)-7.42%
EPS NQ rev (3m)-7.94%
EPS NY rev (1m)-0.17%
EPS NY rev (3m)-0.32%
Revenue NQ rev (1m)1.14%
Revenue NQ rev (3m)1.12%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-0.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.62 | ||
| Fwd PE | 15.53 | ||
| P/S | 5.11 | ||
| P/FCF | 14.42 | ||
| P/OCF | 14.01 | ||
| P/B | 19.12 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.95 |
EPS(TTM)21.87
EY6.4%
EPS(NY)22
Fwd EY6.44%
FCF(TTM)23.69
FCFY6.94%
OCF(TTM)24.38
OCFY7.14%
SpS66.82
BVpS17.87
TBVpS-59.8
PEG (NY)1.9
PEG (5Y)2.62
Graham Number93.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| ROCE | 17.67% | ||
| ROIC | 15.39% | ||
| ROICexc | 17.86% | ||
| ROICexgc | 61.56% | ||
| OM | 33.57% | ||
| PM (TTM) | 19.47% | ||
| GM | 72.06% | ||
| FCFM | 35.46% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
ROICexc(3y)15.77%
ROICexc(5y)17.27%
ROICexgc(3y)75.76%
ROICexgc(5y)77.1%
ROCE(3y)14.97%
ROCE(5y)16.28%
ROICexgc growth 3Y3.26%
ROICexgc growth 5Y-18.2%
ROICexc growth 3Y-8.67%
ROICexc growth 5Y-7.85%
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
F-Score7
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.45 | ||
| Debt/FCF | 4.28 | ||
| Debt/EBITDA | 2.97 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.3% | ||
| Profit Quality | 182.08% | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | N/A |
F-Score7
WACC8.51%
ROIC/WACC1.81
Cap/Depr(3y)24.77%
Cap/Depr(5y)23.42%
Cap/Sales(3y)3.59%
Cap/Sales(5y)3.31%
Profit Quality(3y)165.92%
Profit Quality(5y)155.23%
High Growth Momentum
Growth
EPS 1Y (TTM)13.79%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%1.08%
EPS Next Y8.22%
EPS Next 2Y5.36%
EPS Next 3Y4.87%
EPS Next 5Y4.18%
Revenue 1Y (TTM)10.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%12.4%
Revenue Next Year7.43%
Revenue Next 2Y4.6%
Revenue Next 3Y3.97%
Revenue Next 5Y3.22%
EBIT growth 1Y93.73%
EBIT growth 3Y1.84%
EBIT growth 5Y-0.13%
EBIT Next Year39.98%
EBIT Next 3Y10.33%
EBIT Next 5Y7.12%
FCF growth 1Y36%
FCF growth 3Y7.44%
FCF growth 5Y4.03%
OCF growth 1Y24.04%
OCF growth 3Y7.45%
OCF growth 5Y4.66%
AMGEN INC / AMGN FAQ
Can you provide the ChartMill fundamental rating for AMGEN INC?
ChartMill assigns a fundamental rating of 5 / 10 to AMGN.
Can you provide the valuation status for AMGEN INC?
ChartMill assigns a valuation rating of 6 / 10 to AMGEN INC (AMGN). This can be considered as Fairly Valued.
What is the profitability of AMGN stock?
AMGEN INC (AMGN) has a profitability rating of 7 / 10.
What are the PE and PB ratios of AMGEN INC (AMGN) stock?
The Price/Earnings (PE) ratio for AMGEN INC (AMGN) is 15.62 and the Price/Book (PB) ratio is 19.12.
What is the financial health of AMGEN INC (AMGN) stock?
The financial health rating of AMGEN INC (AMGN) is 3 / 10.